FIELD: medicine.
SUBSTANCE: present invention refers to pharmaceutics and medicine, and concerns the use of 40-O-(2-hydroxyethyl)rapamycin for treating renal angiomyolipoma, lymphangioleiomyomatosis, subependimal astrocytoma and/or giant cell astrocytoma and a based pharmaceutical composition.
EFFECT: invention provides higher clinical effectiveness.
3 cl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING NEUROENDOCRINE TUMOURS | 2006 |
|
RU2487711C2 |
| COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER | 2007 |
|
RU2452492C2 |
| COMBINATIONS OF THERAPEUTIC AGENTS APPLICABLE FOR TREATING CANCER | 2007 |
|
RU2447891C2 |
| COMBINATIONS OF THERAPEUTIC AGENTS FOR CANCER TREATMENT | 2007 |
|
RU2449788C2 |
| APILIMOD FOR USE IN TREATING RENAL CANCER | 2015 |
|
RU2727802C2 |
| TREATING FIBROTIC DISEASES | 2007 |
|
RU2491934C2 |
| COMBINATIONS OF HSP90 INHIBITOR | 2009 |
|
RU2519673C2 |
| ANTHRANILIC ACID AMIDES, METHOD FOR THEIR PREPARING AND THEIR USING, METHOD FOR TREATMENT OF NEOPLASM DISEASE AMD PHARMACEUTICAL DRUG POSSESSING INHIBITORY ACTIVITY WITH RESPECT TO TYROSINE KINASE VEGF RECEPTOR | 2002 |
|
RU2318811C2 |
| COMBINATION CONTAINING IRON COMPLEX AND ANTINEOPLASTIC AGENT, AND USE THEREOF | 2007 |
|
RU2469721C2 |
| CANCER MEDICAL TREATMENT | 2005 |
|
RU2325906C2 |
